Why is ziconotide given intrathecally?

Ziconotide does not cross the blood-brain barrier in therapeutic amounts and would require extremely high systemic doses to achieve spinal analgesia, causing severe side effects. Intrathecal delivery (directly into the cerebrospinal fluid via an implanted pump) allows precise targeting of spinal cord N-type calcium channels with minimal systemic exposure. This route is essential for both efficacy and safety.

Is ziconotide an opioid?

No. Ziconotide is not an opioid and does not interact with mu, kappa, or delta opioid receptors. It is a calcium channel blocker derived from cone snail venom. This means it has zero risk of respiratory depression, opioid-induced hyperalgesia, or addiction. However, it carries a black box warning for severe neuropsychiatric adverse effects (psychosis, hallucinations, paranoia) that require careful patient selection and monitoring.

Treatment hubFDA ApprovedDeep Dive

Ziconotide Treatment Guide: Prialt, Cost and Provider Paths

In the United States, Ziconotide is an FDA-approved peptide therapy. Management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by James Patterson, MD, Board-Certified in Sports Medicine and Physical Medicine & Rehabilitation.

Last reviewed: April 27, 2026

Overview

Ziconotide is a synthetic peptide analog of omega-conotoxin MVIIA, derived from the venom of the cone snail Conus magus. It is the first non-opioid intrathecal analgesic approved by the FDA for severe chronic pain. It acts by blocking N-type calcium channels in the spinal cord, preventing neurotransmitter release from pain-signaling neurons.

Approved Product Paths

Prialt

Branded ziconotide pathway. Management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments

Benefits

•First non-opioid intrathecal analgesic for severe chronic pain
•No risk of respiratory depression or opioid addiction
•Effective for neuropathic and nociceptive pain refractory to other therapies
•No development of tolerance with long-term use

Side Effects & Friction

•Neuropsychiatric effects (confusion, hallucinations, paranoia, mood changes)
•Dizziness, headache, somnolence
•Nausea and vomiting
•Gait abnormalities and nystagmus

Administration Routes

Intrathecal infusion

Cost Reality

Ziconotide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in sleep & stress who can evaluate whether Ziconotide fits the patient's clinical profile and insurance constraints.

How Ziconotide Works

Ziconotide is a synthetic 25-amino-acid peptide omega-conotoxin derived from the cone snail Conus magus. It is a selective N-type calcium channel blocker administered intrathecally for severe chronic pain refractory to other therapies.

Ziconotide is a synthetic version of omega-conotoxin MVIIA, a peptide toxin from the venom of the marine cone snail Conus magus. It selectively blocks N-type voltage-gated calcium channels (Cav2.2) on primary nociceptive afferent terminals in the spinal cord dorsal horn.

N-type calcium channels mediate neurotransmitter release (glutamate, substance P, CGRP) from presynaptic nociceptive terminals. By blocking these channels, ziconotide inhibits synaptic transmission of pain signals to second-order neurons without affecting other calcium channel subtypes.

Unlike opioids, ziconotide does not act on mu-opioid receptors and carries no risk of respiratory depression, tolerance, or addiction. However, it has significant CNS side effects including psychiatric symptoms.

Because ziconotide is a peptide, it cannot cross the blood-brain barrier in significant amounts when given systemically. Intrathecal administration via implanted pump delivers drug directly to the cerebrospinal fluid.

The selectivity for N-type channels means ziconotide does not affect L-type cardiac calcium channels or skeletal muscle excitation-contraction coupling. Cardiovascular and motor effects are minimal.

Onset of analgesia is gradual over days to weeks. Dose titration must be slow due to risk of severe neuropsychiatric adverse effects.

N-type voltage-gated calcium channel (Cav2.2)Presynaptic nociceptive terminalsSpinal cord dorsal horn

Clinical Trial Evidence

Severe chronic pain trials

Population: Patients with severe chronic pain (malignant and non-malignant) refractory to systemic therapy

N= 256

Duration: Variable (chronic therapy)

Endpoint: Pain reduction (VAS)

Significant pain reduction in ~50% of patients at optimal dose
Benefit sustained with chronic intrathecal infusion
No tolerance or dose escalation required over months
Discontinuation rate ~25% due to adverse effects

Dosing & Administration

Severe chronic pain (Prialt)Intrathecal · Continuous intrathecal infusion

Starting: 0.1 mcg/hour via implanted pump

Titration: Increase by 0.1-0.2 mcg/hour no more than 2-3 times per week; maximum increase 2.4 mcg/hour per day

Maintenance: 0.1-0.8 mcg/hour (typical); up to 10 mcg/day maximum

Maximum: 10 mcg/day (0.42 mcg/hour)

•Requires implantable intrathecal pump and catheter
•Must be administered by physicians experienced in intrathecal therapy
•Slow titration is essential to minimize neuropsychiatric adverse effects
•Monitor closely for confusion, hallucinations, and mood changes
•Do not discontinue abruptly; taper gradually to avoid rebound pain

Side Effect Profile

Neuropsychiatric (most serious)

Confusionsevere15%

May require dose reduction or discontinuation

Hallucinationssevere10%

Visual or auditory; reversible with dose reduction

Dizzinessmoderate20%

Common

Sedationmoderate15%

May impair functioning

Depression/suicidal ideationsevere5%

Boxed warning; requires monitoring

Neuromuscular

Nystagmusmoderate8%

May indicate excessive dose

Ataxiamoderate5%

Gait instability

Memory impairmentmoderate5%

Cognitive effects

Other

Nauseamoderate25%

Common

Headachemild15%

Usually mild

Urinary retentionmoderate5%

Requires monitoring

Contraindications & Warnings

Do Not Use

History of psychosis
Untreated depression or suicidal ideation
Bleeding diathesis or anticoagulation (intrathecal insertion risk)
Spinal canal obstruction preventing catheter placement
Hypersensitivity to ziconotide

Important Warnings

Boxed warning for severe psychiatric symptoms and neurological impairment. Patients must be monitored closely. Dose reduction or discontinuation may be required.
Suicidal ideation and depression: screen before initiation and monitor throughout therapy.
Cognitive impairment: may affect memory, attention, and executive function. Patients should not drive or operate machinery until stable.
Meningitis risk: intrathecal delivery carries infection risk. Use aseptic technique.
Sudden discontinuation may cause rebound severe pain.

Drug Interactions

Drug	Interaction	Severity	Mechanism
CNS depressants	Additive sedation and confusion	major	Synergistic CNS depression
Intrathecal opioids	May be combined cautiously	moderate	Some patients benefit from combination; monitor carefully

Monitoring Requirements

Mental status examination at every visit
Mood and suicidal ideation screening
Cognitive function (memory, attention)
Neurological examination (nystagmus, ataxia)
Pain scores and functional status
Pump function and catheter integrity
Signs of meningitis (fever, headache, neck stiffness)

How Ziconotide Compares

Respiratory depressionZiconotide advantage

Ziconotide: None

Intrathecal morphine: Risk present

Major safety advantage in patients with respiratory compromise

Psychiatric side effectsIntrathecal morphine advantage

Ziconotide: Severe

Intrathecal morphine: Mild-moderate

Ziconotide's neuropsychiatric effects are its major limitation

ToleranceZiconotide advantage

Ziconotide: No tolerance

Intrathecal morphine: Tolerance develops

Ziconotide does not require dose escalation over time

RouteOral opioids advantage

Ziconotide: Intrathecal (invasive)

Oral opioids: Oral (non-invasive)

Intrathecal therapy requires pump implantation

InvasivenessSpinal cord stimulation advantage

Ziconotide: Intrathecal pump

Spinal cord stimulation: Epidural leads

Both invasive; patient selection depends on pain type and anatomy

Evidence Quality Assessment

Overall Evidence Grade: B

A = Strong evidence from multiple large RCTs

Human RCTs: Moderate: Several RCTs in refractory pain; limited by small sample sizes

Long-term data: Limited: Chronic infusion data available but largely open-label

Real-world evidence: Limited: Used in specialized pain centers; not first-line

Regulatory status: FDA-approved for severe chronic pain refractory to other therapies

Is Ziconotide Right for You?

Ideal Candidates

Patients with severe chronic pain (malignant or non-malignant) refractory to oral/transdermal opioids and adjuvants
Patients with respiratory compromise who cannot tolerate systemic opioids
Those who have developed significant opioid tolerance or hyperalgesia
Patients with implanted intrathecal pump who need non-opioid intrathecal agent

Avoid

History of psychosis, severe depression, or suicidal ideation
Patients unable to comply with frequent monitoring
Those without access to experienced intrathecal therapy center
Patients with uncontrolled bleeding risk
Patients seeking mild or moderate pain relief (overkill for mild pain)

Use With Caution

Depression or anxiety disorders
Elderly patients (increased confusion risk)
Patients on other CNS depressants
Impaired renal function (may affect drug clearance)

Cost & Insurance Deep Dive

List Price (Monthly)

~$2,500-$3,500/month (drug only); pump and procedure costs additional

Cash-Pay Range

$2,500-$3,500/month for drug

Insurance Coverage Rate

~70-80% for refractory pain with prior auth

Prior Auth Likelihood

Extremely high; requires documentation of failure of multiple analgesic classes and specialist attestation

Savings Programs

Manufacturer patient assistanceMay provide drug at reduced or no cost

Eligibility: Uninsured/underinsured

Case-by-case

Cost-Effectiveness Notes

•Drug cost is only part of total therapy cost; pump implantation, refills, and monitoring add substantially
•May reduce overall healthcare utilization in refractory pain patients
•Cost is justified only when all less invasive options have failed
•Specialized centers required; limited geographic availability

Ready to find a ziconotide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a ziconotide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Ziconotide FAQ

Sources

1. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
J Pain Symptom Manage • 2006
Claim type: clinical
View source →
2. FDA Information on Ziconotide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.